Heme Oxygenase-1 Exerts a Protective Role in OVA-induced Neutrophilic Airway Inflammation by Inhibiting Response in the Immune Cells Th 17
Yanjie Zhang,Liya Zhang,Jinhong Wu,C. Di,Z. Xia
2013-01-01
Abstract:Allergic asthma is conventionally considered as a Th2 immune response characterized by eosinophilic inflammation. Recent investigations revealed that Th17 cells play an important role in the pathogenesis of non-eosinophilic asthma (NEA), resulting in steroid-resistant neutrophilic airway inflammation. Heme oxygenase-1 (HO-1) has anti-inflammation, anti-oxidation and anti-apoptosis functions. However, its role in NEA is still unclear. Here, we explore the role of HO-1 in a mouse model of NEA. HO-1 inducer hemin or HO-1 inhibitor tin protoporphyrin IX (SnPP) were injected intraperitoneally into ovalbumin (OVA)-challenged DO11.10 mice. Smallinterfering RNA (siRNA) was delivered into mice to knock down HO-1 expression. The results show that induction of HO-1 by hemin attenuated airway inflammation and decreased neutrophil infiltration in bronchial alveolar lavage fluid (BALF) and was accompanied by a lower proportion of Th17 cells in mediastinal lymph nodes and spleen. More importantly, induction of HO-1 down-regulated Th17-related transcription factor retinoic acid-related orphan receptor γt (RORγt) expression and decreased IL-17A level, all of which correlated with a decrease in phosphorylated STAT3 (p-STAT3) level and inhibition of Th17 cell differentiation. Consistently, the above events could be reversed by SnPP. Also, HO-1 siRNA transfection abolished the effect of hemin induced HO-1 in vivo. Meanwhile, the hemin treatment promoted the level of Foxp3 expression and enhanced the proportion of regulatory T cells (Tregs). Collectively, our findings indicate that HO-1 exhibits anti-inflammatory activity in the mouse model of NEA via inhibition of the p-STAT3-RORγt pathway, regulating kinetics of RORγt and Foxp3 expression, thus providing a possible novel therapeutic target in asthmatic patients. Asthma is a common chronic inflammatory disease, the incidence of which is gradually increasing worldwide due to factors such as environmental pollution. It is of particular concern that severe asthma comprises an important source of morbidity in asthmatic patients and brings a tremendous economic burden to society. Classically, eosinophilic inflammation mediated by Th2 cells is considered a hallmark of asthma. However, recent studies using sputum induction http://www.jbc.org/cgi/doi/10.1074/jbc.M113.494369 The latest version is at JBC Papers in Press. Published on October 4, 2013 as Manuscript M113.494369 Copyright 2013 by The American Society for Biochemistry and Molecular Biology, Inc. by gest on O cber 5, 2017 hp://w w w .jb.org/ D ow nladed from HO-1 suppresses Th17-mediated neutrophilic airway inflammation 2 and bronchial alveolar lavage (BAL) techniques indicate that about 50% of asthma is based on non-eosinophilic inflammation involved polymorphonuclear neutrophils (PMNs), mast cells, leukomonocytes, and macrophages (1-3). These findings suggest that severe asthma may be a different subtype, namely non-eosinophilic asthma (NEA), rather than just an increase in asthma symptoms per se (4). Different from patients with eosinophilic asthma (EA), patients with NEA exhibit non-Th2-type airway inflammation characterized by increased neutrophil levels without elevation of serum IgE (5). Studies indicate that Th17 cells play a crucial role in neutrophilic inflammation, as they secrete IL-17 to induce granulopoiesis, neutrophil chemotaxis and the anti-apoptotic properties of granulocyte-colony stimulating factor (G-CSF) (6). Clinical evidence has also shown that gene expression of IL-17 is elevated in asthmatic patients, a circumstance that is correlated with clinical severity (7). Notably, Th17 cell-mediated airway inflammation and airway hyperresponsiveness are steroid-resistant (8). Therefore, it is imperative to explore novel therapeutic strategies for NEA. Heme oxygenase (HO) is a rate-limiting enzyme for heme metabolism, which catalyzes heme into carbon monoxide (CO), biliverdin and free iron. Three HO isozymes have been identified, including inducible HO-1, constitutive HO-2 and isomer HO-3. HO-1 is a ubiquitous stress-inducible protein with broad physiological anti-apoptotic, anti-proliferation and immunoregulatory functions (9-12). As a substrate of HO-1, hemin is widely used to induce HO-1, exerting a protective effect in a variety of animal models (13-15). It is reported that the expression of HO-1 protein and its activity are significantly increased after hemin treatment, whereas the competitive inhibitor tin protoporphyrin IX (SnPP) induces the expression of HO-1 accompanied by blocked enzymatic activity in both animal models and cultured cells (16-21). Our previous studies indicate that induction of HO-1 by hemin is able to suppress allergic airway inflammation in a mouse model of EA (16). The current study sets out to examine the effect of HO-1 induction on Th17-mediated neutrophilic airway inflammation in DO11.10 TCR-transgenic mice and investigate the mechanism by which HO-1 regulates Th17 immunity. EXPERIMENTAL PROCEDURES Mice—DO11.10 TCR-transgenic (Tg) mice on a BALB/c background were purchased from Model Animal Research Center of Nanjing University and maintained in specific pathogen-free conditions in the Research Center for Experimental Medicine of Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine. All animal experiments were approved by and performed in compliance with the guidelines of the Ethics Committee of Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine. Induction of the non-eosinophilic asthma model and administration of hemin or SnPP—Six to eight week-old female DO11.10 Tg mice were randomly divided into four groups including OVA, OVA+hemin, OVA+SnPP, and control groups (n=6 in each group). The mice in OVA, OVA+hemin and OVA+SnPP groups were intranasally challenged with 100 μg of OVA (Sigma-Aldrich) in 50 μl of normal saline (NS) after anesthetization by inhalation of isoflurane on days 0, 1, and 2. The mice in the control group were intranasally challenged with NS. All animals were sacrificed on day 3. Mice were intraperitoneally administered 75 μmol/kg of hemin (Sigma-Aldrich) or 75 μmol/kg of SnPP (Porphyrin Products) on days -2 and -1 in OVA+hemin and OVA+SnPP groups, respectively. Hemin or SnPP was dissolved in 0.2 mol/L NaOH, titrated to pH 7.4 with 0.2 mol/L HCl, and then diluted with phosphate-buffered saline (PBS). BALF—Twenty-four hours after the final challenge (day 3), all mice were anaesthetized with isoflurane and sacrificed after collecting blood via the ophthalmic vein. After blunt dissection of the tracheas, the lungs were lavaged three times with ice-cold saline (0.4 ml each) using a 22-gauge i.v. catheter and the bronchoalveolar lavage fluid (BALF) was collected. This procedure recovered 80 to 90% of the infused fluid. The collected BALF was centrifuged at 453 x g at 4°C for 5 minutes. The supernatant was then stored at -80°C before further study. The cells were resuspended in 0.5 ml PBS, and the total cell numbers were counted with by gest on O cber 5, 2017 hp://w w w .jb.org/ D ow nladed from HO-1 suppresses Th17-mediated neutrophilic airway inflammation 3 a hemocytometer. A small amount of the cell suspension was fixed in 95% ethanol for 30 minutes for routine H&E staining. On the basis of the findings with H&E stain, cell differentials were counted with at least 200 leukocytes in each sample under the microscope (Olympus AX70, Japan). The cell types were judged according to standard hemocytologic procedures as macrophages, neutrophils, lymphocytes or eosinophils. Histopathology—After perfusion with PBS, the right low pulmonary lobes were resected and fixed with 10% neutral buffered formalin and embedded in paraffin. Four-micrometer-thick sections were stained with H&E. Real-time PCR—Lung tissue was removed and homogenized and total RNA was extracted with TRIzol reagent (Invitrogen Life Technologies, Carlsbab, CA) according to the manufacturer’s instructions. Reverse transcription was performed using PrimeScript reverse transcriptase (TaKaRa, Japan) to obtain cDNA samples. Real-time PCR was performed using an ABI Prism 7300 (Applied Biosystems) with the following program: 95°C for 10 seconds and 40 cycles of amplification at 95°C for 5 seconds, 60°C for 31 seconds and 95°C for 15 seconds, finally, 60°C for 30 seconds and 95°C for 15 seconds. Relative levels of target mRNA were compared with β-actin using the 2 method. All primers were synthesized by Shanghai Shengon Biotech Company (Shanghai, China). Sequences were as follows: β-actin Forward: 5'-GGC TGT ATT CCC CTC CAT CG-3', Reverse: 5'-CCA GTT GGT AAC AAT GCC ATG T-3'; Foxp3 Forward: 5'-CAC AAT ATG CGA CCC CCT TTC-3', Reverse: 5'-AAC ATG CGA GTA AAC CAA TGG TA-3'; RORγt Forward: 5'-GAC CCA CAC CTC ACA AAT TGA -3', Reverse: 5'-AGT AGG CCA CAT TAC ACT GCT-3'; T-bet Forward: 5'-TTT CCA AGA GAC CCA GTT CAT TG-3', Reverse: 5'-ATG CGT ACA TGG ACT CAA AGT T-3'; GATA-3 Forward: 5'-CTC GGC CAT TCG TAC ATG GAA-3', Reverse: 5'-GGA TAC CTC TGC ACC GTA GC-3'. Western blot analysis—Lung tissues were homogenized with ice-cold RIPA buffer (Beyotime, Shanghai, China) containing protease inhibitors. Whole-cell extracts from CD4 T cells stimulated with recombinant IL-6 (R&D System) or IL-2 (R&D System) were also obtained utilizing ice-cold RIPA buffer. The extracts containing 30 μg proteins were separated on 12% SDS-PAGE and then transferred to polyvinylidene fluoride membranes. The membrane was blocked with Trisbuffered saline Tween-20 (TBST) buffer containing 5% skim milk and incubated with the following primary antibodies: rabbit anti-mouse RORγt IgG (1/1000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA); rabbit anti-mouse IgG Foxp3 (1/1000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA); mouse anti-mouse phosphorylated STAT3 (p-STAT3) (Tyr705) (1/1000 dilution, Cell Signaling); mouse anti-mouse phosphor-Stat5 (Tyr694) (1/1000 dilution, Cell Signaling). The samp